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Summary Experimental data show that ATP-sensi- 
tive potassium (KATP) channels not only occur in pan­
creatic beta cells, but also in the cardiovascular sys­
tem, where they mediate important cardioprotective 
mechanisms. Sulphonylurea derivatives can block 
the cardiovascular KATP channels and may therefore 
interfere with these cardioprotective mechanisms. 
Therefore, it is of clinical importance to investigate 
whether sulphonylurea derivatives interact with vas­
cular Katp channels in humans. Using venous-occlu- 
sion strain-gauge plethysmography, we investigated 
whether ischaemia-induced reactive hyperaemia is 
reduced by the sulphonylurea derivative glibencla- 
mide in 12 healthy male non-smoking volunteers. 
Forearm vasodilator responses to three periods of ar­
terial occlusion (2, 5 and 13 min) during concomitant 
infusion of placebo into the brachial artery were com­
pared with responses during concomitant intra-arte- 
rial infusion of glibenclamide (0.33 ¡ag • min'1 • dl"1). 
A control study (n = 6) showed that time itself did 
not change the vasodilator response to ischaemia.
Glibenclamide significantly increased minimal vascu­
lar resistance (from 2.1 ± 0.1 to 2.3 ± 0.2 arbitrary 
units, Student’s i-test: /? = 0.01), and reduced mean 
forearm blood flow (from 37.5 ± 2.0 to 35.4 ± 2.0 ml • 
mill-1 • dl”1 after 13 min occlusion, ANOVA with re­
peated measures: p  = 0.006) and flow debt repayment 
during the first reperfusion minute (ANOVA with re­
peated measures: p  = 0.04). In contrast, total flow 
debt repayment was not affected. Infusion of glib­
enclamide into the brachial artery resulted in local 
concentrations in the clinically relevant range, 
whereas the systemic concentration remained too 
low to elicit hypoglycaemic effects. Our results sug­
gest that therapeutic concentrations of glibenclamide 
induce a slight but significant reduction in the early 
and peak vasodilation during reactive hyperaemia. 
[Diabetoiogia (1996) 39:1562-1568]
Keywords ATP-sensitive potassium channels, glib­
enclamide, reactive hyperaemia, ischaemia, forearm 
blood flow.
In 1983, Noma [1] was the first to describe that an 
outward potassium current increased significantly 
when guinea pig or rabbit cardiac muscle cells were 
subjected to hypoxia. This current was caused by the
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Abbreviations'. [ATP]i( Intracellular ATP concentration; AU, 
arbitrary unit; dl, decilitre = 100 ml (forearm volume); FBF, 
forearm blood flow; FVR, forearm vascular resistance; KATP 
channel, ATP-sensitive potassium channel; l-NMMA, Ng- 
mono-methyl-L-arginine; NIDDM, non-insulin-dependent di­
abetes mellitus.
activation of potassium channels, which was indepen­
dent of the intracellular Ca2+ concentration, but de­
pendent on the intracellular concentration of adenos­
ine-5 '-triphosphate ([ATP]j). These so-called ATP- 
sensitive potassium (KATP) channels were suggested 
to play a cardioprotective role during ischaemia. La­
ter, Katp channels were also found in skeletal muscle 
[2], smooth muscle [3] and pancreatic beta cells [4] 
from animals. In pancreatic beta cells the KATP chan­
nels mediate insulin secretion [5] and are a target for 
sulphonylurea derivatives in the treatment of non-in­
sulin-dependent diabetes mellitus (NIDDM) [6]. Sul­
phonylurea derivatives are highly specific in blocking 
pancreatic and cardiovascular KAXP channels, and
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Table 1. Characteristics of the male non-smoking volunteers
Experimental Control
group group
n ~ 12 n = 6
Age (years) 28.2 + 7.7 27.5 ± 9.5
Body mass index (kg/m2) 22.3 ±  2.0 21.9 ± 1 .8
Systolic blood pressure (m m H g) 125 ±  10 127 ± 6
Diastolic blood pressure (m m  Fig) 69 ± 7 74 ± 9
Heart rate (beats/min) 64 ± 7 60 ± 7
Data are means ±SD. Blood pressure was measured with a 
sphygmomanometer and heart rate after 5 min supine rest dur­
ing the pre-investigation visit
therefore, have been widely used to study the role of 
Katp channels in the regulation of insulin secretion, 
cardiac function and vascular tone. Under ischaemic 
conditions the opening of cardiovascular KATP chan­
nels triggers endogenous cardioprotective mecha­
nisms which prevent a further ATP depletion by 
shortening of action potential with a decrease in con­
traction [7] and by vasodilation which results in an in­
creased oxygen supply [8]. These mechanisms protect 
the myocardium against. ischaemia and reperfusion 
damage and improve mechanical function during re­
perfusion [9], The protective effects of ischaemic pre­
conditioning have also been suggested to be m edi­
ated by opening of cardiovascular KATP channels [10, 
11]. On the other hand, opening of KATP channels 
may increase the incidence of arrhythmias [12, 13]. 
As a result, in all kinds of animal models the cardio­
vascular consequences of blockade of K ATP channels 
by sulphonylurea derivatives are diverse, with exten­
sion of infarct size on the one hand [14] and reduction 
of fatal arrhythmias on the other [12,13].
All these effects of sulphonylurea derivatives have 
been demonstrated in animal models but, there are 
several arguments to suggest that they may also occur 
in humans [15]. Until now, data in humans on this im­
portant issue are very scarce. One of the first steps in 
this field must be to investigate whether a pathophys­
iological stimulus of the above-mentioned mecha­
nism can be inhibited by therapeutic concentrations 
of sulphonylurea derivatives in man. Therefore, we 
now investigate in vivo in the human forearm 
whether ischaemia-induced vasodilation can be re­
duced by local therapeutic concentrations of the sul­
phonylurea derivative glibenclamide.
Subjects and methods
The study protocol was approved by the local ethics commit­
tee, and 18 healthy male non-smoking volunteers with a nor­
mal medical history, physical examination and blood pressure 
gave written, informed consent before entering the study. 
Their characteristics are listed in Table 1. They were instructed 
to abstain from caffeine-containing beverages and alcohol for 
at least 24 h before the experiment. Furthermore, they were
asked to eat a light meal 2 h before the experiment was started 
and to abstain from further food intake until the end of the ex­
periments. Forearm volume was measured by water displace­
ment. Each subject participated in only one experiment. All 
experiments were performed in the afternoon with the subjects 
in the supine position in a quiet, temperature-controlled room 
(22 °C) to ensure that forearm blood flow (FBF) predomi­
nantly referred to forearm muscle perfusion [16, 17].
Effect o f  glibenclamide on ischaemia-induced forearm vasodi­
lation. In 12 subjects (experimental group) a cannula (Angio- 
cath, 20 gauge; Deseret Medical Inc., Becton Dickinson and 
Company, Sandy, Utah, USA) was inserted under local anaes­
thesia (xylocaine 2 % )  into the left brachial artery for blood 
pressure measurement with a single line customer kit (Viggo- 
Spectramed, No 992399A/14368; Bilthoven, The Netherlands) 
and a Hewlett Packard monitor (type 78353B; Hewlett Pack­
ard GmbH, Boblingen, Germany), and for intra-arterial drug 
infusion with an automated syringe infusion pump (type STC- 
521; Terumo Corporation, Tokyo, Japan). Drugs were infused 
at a volume rate of 100 (¿1 * min“1 * d r 1 of forearm volume. 
Forearm blood flow was measured by ECG-triggered venous 
occlusion mercury-in-silastic strain-gauge plethysmography 
(Hokanson EC4, D. E.; Hokanson Inc., Issaquah, Wash., 
USA), Four FBF curves per min were recorded. During all re­
cordings of the FBF, the hand circulation was completely oc­
cluded by a wrist cuff inflated 100 mmHg above the systolic 
blood pressure to ensure that measurements only referred to 
the forearm skeletal muscle vascular bed [18]. A neighbouring 
and a contralateral antecubital vein were cannulated for blood 
sampling. Arterial occlusion of the forearm was obtained by 
inflating an extra cuff on the left upper arm to 100 mmHg 
above systolic blood pressure.
Figure 1 shows the course of the test. After an equilibration 
period of 35 min infusion of placebo (physiological saline) into 
the brachial artery was started. After 10 min, baseline mea­
surements of blood pressure, heart rate and FBF were taken 
during 5 min with concomitant intra-arterial infusion of pla­
cebo. Then, the FBF, in response to three increasing periods 
of forearm ischaemia (2, 5 and 13 min), was recorded during
3, 5 and 5 min post-occlusive reperfusion time, respectively. 
During the last minute of the 13 min occlusion period subjects 
performed forearm exercise, inducing a maximal forearm va­
sodilation during reperfusion [19]. Infusions were interrupted 
10 s after the start of arterial occlusion until 10 s before the 
end of occlusion.
After a subsequent equilibration of 40 min to allow param­
eters to return towards baseline levels, baseline values, were 
again recorded, during concomitant infusion of placebo. Then 
a second series of experiments with 2, 5 and 13 min of forearm 
ischaemia was performed, but with concomitant intra-arterial 
infusion of glibenclamide (0.33 fxg • min“1 • dl”1) instead of pla­
cebo. This infusion rate leads to local forearm glibenclamide 
concentrations which are similar to systemic concentrations as 
reached daily during the treatment of NIDDM  [20, 21]. In this 
way the effect of therapeutic glibenclamide concentrations on 
the forearm vasodilator response to ischaemia was assessed lo­
cally.
Venous blood samples for insulin and C-peptide determina­
tions were taken from the non-experimental arm before and at 
the end of the glibenclamide infusion and before the start of 5 
and 13 min of arterial occlusion. Before each occlusion period, 
venous blood samples from the experimental side were taken 
for the determination of local glibenclamide concentrations. 
A t all these sampling points, the plasma glucose concentration 
was measured immediately by a Glucocard glucose analyzer 
(type GT-1610; Kyoto Daiichi Kagaku Co., Kyoto, Japan).
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Fig. 1. Schematic view of the course of the protocol, indicating 
periods of arterial occlusion and flow measurements during 
concomitant infusion of placebo or glibenclamide
Statistical analysis
To avoid multiple comparison and to investigate a shift of the 
stimulus response curves, within subject effects were statisti­
cally analysed by an analysis of variance (ANOVA) with re­
peated measures over all periods of ischaemia, and post-hoc 
paired Student’s i-test were used to show after which stimuli 
inhibition was most pronounced. The SPSS PC + 3.0 program 
(Statistical Package for Social Sciences) was used, and 
p  < 0.05 was considered statistically significant. Values pre­
sented are means ± SEM, unless indicated otherwise.
Because of the long half-life, high protein binding [20, 21] and 
possible incorporation of sulphonylurea derivatives in the plas­
ma membrane [22], randomization of placebo and glibencla­
mide infusion was not possible because of carry-over effects.
Time-control study. In order to eliminate confounding factors 
such as time and the repeat of the procedure in the above-de- 
scribed protocol, a control study was performed.
In six subjects (control group) the above-described proto*- 
col was performed in the same manner, except that glibencla­
mide was not used in the second part. Therefore, placebo infu­
sions and consequently an arterial line were not necessary. The 
repeat of the ischaemia-induced vasodilator responses was 
preceded by one baseline determination. Furthermore, no 
blood samples for insulin, C-peptide or glucose were taken. In­
stead, blood pressure was obtained with an automated record­
ing device (Dinamap, type 1846 SX/P Critikon, Tampa, Flori­
da, USA) every minute on the non-experimental arm.
Humoral parameters. For glibenclamide determinations, ve­
nous blood samples were collected in glass tubes without addi­
tives. After 20 min the blood was centrifuged at 3000 rev/min 
for 10 min; serum was then frozen at -20 °C. In these serum 
samples drug concentrations were determined at the laborato­
ries of Hoechst AG, Frankfurt, Germany. Glibenclamide was 
determined, using a validated specific radioimmunoassay 
(RIA) [23]v The detection limit was 1-3 ng/ml.
Insulin and C-peptide concentrations were determined in 
venous blood samples collected in chilled glass tubes coated 
with lithium-heparin. Tire blood was centrifuged at 3000 rev/ 
min for 10 min. Then plasma was frozen at -20 °C. In these 
samples insulin and C-peptide were determined in our labora­
tories using specific RIAs. C-peptide was measured with a 
standard kit (D.P.C., Los Angeles, Calif., USA). In the insulin 
assay, standard and tracer insulin was prepared from mono­
component human insulin (Novo, Zoeterwoude, The Nether­
lands).
Calculations. Forearm vascular resistance (FVR) was calcu­
lated as the quotient of mean arterial pressure and simulta­
neously measured FBF, and expressed as arbitrary units 
(AU). Baseline values were averaged to one mean representa­
tive value. During each reperfusion period after an ischaemic 
stimulus, maximal FBF and minimal FVR, as well as the mean 
FBF and FVR during the first reperfusion minute were deter­
mined. Flow debt was determined as the preocclusion baseline 
FBF multiplied by the duration of occlusion. Flow debt repay­
ment was determined as the area under the FBF vs the time 
curve during reactive hyperaemia minus preocclusion baseline 
FBF times the duration of reactive hyperaemia. Percent flow 
debt repayment was calculated as flow debt repayment divided 
by flow debt multiplied by 100 [24]. Also, flow debt repayment 
during the first reperfusion minute was computed. Flow debt 
repayment is expressed as ml per dl of forearm volume.
Results
Intra-arterial recordings of baseline systolic and dias­
tolic blood pressure averaged 115 ±13 and 66 ± 
6 mmHg, respectively in the experimental group, 
and 119 ± 6  and 61 ± 8  mmHg in the control group. 
Baseline heart rate was 58 ± 8 and 58 ± 10 beats per 
min in the experimental and control group, respec­
tively. During the experiments these parameters did 
not change.
In both groups the baseline FBFs did not signifi­
cantly change throughout the protocols, and conse­
quently the flow debts caused by the corresponding 
periods of arterial occlusion remained statistically un­
changed.
Forearm vascular responses to ischaemia. The three 
increasing periods of ischaemia resulted in significant 
responses of all flow parameters, with more pro­
nounced responses after longer occlusion times. FBF 
reached a maximal value of 41.9 ± 2.3 ml • min”1 * dl-1 
after 13 min of occlusion (Table 2), and after 2 and 
5 min of ischaemia a 10- to 15-fold increase in base­
line blood flow was reached. FVR reached a mini­
mum value after 13 min ischaemia of 2.1 ± 0.1 AU. 
After 2 and 5 min ischaemia, these FVR values were 
respectively 3.0 ± 0.1 and 2.5 ± 0.2 AU (Fig. 2). Dur­
ing the first reperfusion min mean FBF, mean FVR 
and the flow debt repayment showed significant re­
sponses to ischaemia which increased with the occlu­
sion time (Figs. 2 and 3). Also, total flow debt repay­
ment was increased significantly with the three in­
creasing periods of ischaemia (Table 2).
Effect o f  glibenclamide on responses to ischaemia. In­
fusion of glibenclamide did not change baseline pa­
rameters. Minimal FVR in response to three increas­
ing periods of forearm ischaemia was significantly in­
creased by glibenclamide, with post hoc Mests indi­
cating significant increases in minimal FVR after 2 
and 13 min forearm ischaemia (Fig. 2). Similarly, 
maximal FBF in response to the ischaemic stimuli 
showed a trend to decrease from 41.9 ±2.3 to 
40.8 ± 2.9 ml • dH  * min-1 in the presence of glibencla­
mide (Table 2, p  = 0.07). Glibenclamide significantly 
decreased the mean FBF and increased the mean
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Arterial occlusion Max FBF (ml min 1 • d r 1) Total flow debt repayment (ml • dl"1)
Control
Placebo
Experimental
Placebo
Control
Placebo
Experimental
Placebo
Baseline 2.6 ± 0.6 2.1 ±0.2
2 min 27.9 ±4.4 28.2 ±1.3 239 ± 53 278 ± 34
5 min 35.7 ± 4.6 33.9 ± 2.7 845 ±119 770 ± 69
13 min 45.114.7 41.9 ± 2.3 4178 ±474 4081 ± 225
Baseline 1.9 ±0.2
Placebo Glibenclamide Placebo Glibenclamide
Baseline 1.8 ±0.3 1.8 ±0.2
2 min 28.4 ±2.9 ' 25.8 ± 1.3“ 241 ± 62 224 ± 33a
5 min 34.3 ± 3.3 31.8 ±1.3 70S ±108 627 ± 66
13 min 47.7 ±3.4 40.8 ± 2,9 4085 ± 640 3896 ± 274
p -value 0.74 0.07 0.39 0.14
Data are means ± SEM. Baseline forearm blood flow (FBF), 
maximal FBF and total flow debt repayment during the first re­
perfusion minute after arterial occlusion during concomitant 
infusion of placebo and during the repeat with placebo (con­
trol group) or glibenclamide (experimental group). Within 
subject analysis: p -values from repeated measures ANOVA  
over all ischaemic stimuli. 11 Post-hoc paired f-test p  < 0.05 vs 
preceding corresponding value
FVR during the first reperfusion minute (Fig. 3). 
Post-hoc i-test showed a small but significant increase 
in mean FVR after 13 min ischaemia from 2.4 ± 0.1 to 
2.6 ±0.1 A U  (Fig. 3, p  = 0.02). Moreover, flow debt
repayment during the first reperfusion minute was 
significantly reduced by glibenclamide (Fig. 4). D e­
spite decreased mean flow, increased mean vascular 
resistance and decreased flow debt repayment during 
the first reperfusion minute, the total flow debt re­
payment remained statistically unchanged during 
concomitant infusion of glibenclamide as compared 
with placebo (Table 2). Post-hoc f-test showed that 
total flow debt repayment after 2 min arterial occlu­
sion was significantly decreased by glibenclamide 
(Table 2, p = 0.03). If expressed as percentage flow 
debt repayment, reactive hyperaemia showed a simi­
lar pattern as total flow debt repayment.
Time control study. During the control experiments 
the three increasing periods of ischaemia caused sig­
nificant responses in all flow parameters comparable 
to the experimental group. These changes were not 
significantly influenced by the repeat of the proce­
dure (Figs. 2-4 and Table 2).
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Fig. 2. Minimal forearm vascular resistance (FVR), after three 
periods of forearm ischaemia during concomitant infusion of 
placebo (O* CD ar)d during the repeat ( ^  H )  with placebo in 
the control group (n = 6) or with glibenclamide in the experi­
mental group (n = 12). /j-values refer to ANOVA with re­
peated measures; * post-hoc /'-test p < 0.05, mean ± SEM
Humoral parameters. In the experimental group, sys­
temic insulin, C-peptide and glucose concentrations 
remained stable and were not changed significantly 
throughout the experiments. Insulin ranged from 
7.5 ± 0.8 to 8.1 ± 1.0 mU/1, C-peptide ranged from 
0.38 ± 0.04 to 0.43 ± 0.04 nmol/1 and glucose ranged 
from 4.2 ± 0.2 to 4.5 ± 0.1 mmol/1. Local glibencla­
mide concentrations varied from 65 ± 7 to 53 ± 5 ng/ 
ml during the test and remained within a therapeutic 
range, while systemic glibenclamide concentrations 
were maximally 11.6 ± 1.2 ng/ml at the end of the ex­
periment, and remained below the therapeutic range 
as demonstrated by unchanged insulin levels [20,21].
Discussion
Previous studies in animal models have shown that 
ischaemia-induced vasodilation could be reduced by 
sulphonylurea derivatives, which strongly argues for 
a role of vascular K ATP channels in this response [24, 
25]. Sulphonylurea derivatives such as glibendaniide 
are widely used in the treatm ent of patients with 
NIDDM . Therefore, it is of great clinical importance 
to investigate w hether therapeutic  concentrations of 
sulphonylurea derivatives in hum ans can interact 
with vascular KATP channel-m ediated mechanisms. It 
has to be emphasized tha t experim ental data derived
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Fig. 3. Mean forearm blood flow (FBF, left panels) and mean, 
vascular resistance (FVR, right panels) during the first re-per­
fusion minute after three periods of forearm ischaemia during 
concomitant infusion of placebo (Q> D )  and during the repeat 
( # ,  D  with placebo in the control group (n -  6) or with glib­
enclamide in the experimental group (n — 12). P-values refer 
to ANOVA with repeated measures; *post-hoc f-test p  < 0.05, 
mean ± SEM
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Fig. 4. Flow debt repayment during the first re-perfusion min­
ute after three periods of forearm ischaemia during concomi­
tant infusion of placebo (■ )  and during the repeat (□ )  with 
placebo in the control group (n = 6) or with glibenclamide in 
the experimental group (n = 12). /;-values refer to ANOVA 
with repeated measures; *post-hoc r-test p < 0.05, mean ± SEM
from animal studies are not necessarily relevant to 
the clinical situation of N ID D M  patients because, in 
general, the concentrations of sulphonylurea deriva­
tives used in animal models are much higher. M ore­
over, the high protein binding of sulphonylurea deriv­
atives ( > 99 %) in humans considerably reduces the 
free fraction of the drug which is able to interact 
with the sulphonylurea receptor of the KAXP channel 
[21].
The present study suggests that therapeutic con­
centrations of glibenclamide significantly reduce the 
vasodilator responses to ischaemia in the forearm 
skeletal muscle vascular bed. This glibenclamide ef­
fect particularly concerns the peak vasodilation after 
ischaemia. The time-control study showed that re­
peating the procedure did not change the vasodilator 
response to ischaemia, and therefore, changes during 
the glibenclamide study could not be attributed to 
time effects or to the repeat of the procedure. The re­
sults were not biased by changes in systemic haemo- 
dynamic param eters (blood pressure, heart rate) 
since no significant changes occurred in these param­
eters during the experiments. Our observations oc­
curred at a glibenclamide plasma concentration of 
= 60 ng/ml, which is well within the clinically relevant 
range [21, 26]. Because of the experimental model 
(intra-arterial infusions), these concentrations only 
occurred in the forearm  vascular bed, and therefore 
we were able to avoid possible confounders such as 
increments in systemic insulin levels or hypoglycae- 
mia. Consequently, the current observations show
that the relatively low concentrations of glibencla­
mide, which are likely to occur during the treatment 
of NIDDM, do slightly but significantly reduce the 
peak vasodilation after ischaemia suggesting an inter­
action with vascular Kaxp channels. Recently, Kosmas 
et al. [27] were the first to publish on this issue, but 
they reported on the effects of oral ingestion of 
10 mg of glibenclamide on the baseline and reactive 
hyperaemic blood flow in the calf of healthy volun­
teers. In contrast to our present observations, their re­
sults may have been seriously confounded by hyper- 
insulinaemia, hypoglycaemia, and subsequent stimu­
lation of the sympathetic nervous system.
In this study, we evaluated three different ischae­
mic stimuli: 2, 5 and 13 min of arterial occlusion. 
Pedrinelli and colleagues [19] showed that the 
13 min occlusion of the brachial artery with forearm 
exercise in the last minute, results in a maximal fore­
arm vasodilation during reperfusion. Interestingly, 
glibenclamide not only reduced the vasodilator re­
sponse to this maximal stimulus, but also affected 
the responses to the mild ischaemic stimuli. In gen­
eral, the fall in intracellular ATP-concentration is 
considered to be the main trigger for the activation 
of Katp channels during ischaemia. However, mag­
netic resonance spectroscopy recordings on skeletal 
muscle during ischaemia in humans do not show evi­
dence for a fall in these ATP-concentrations after 
these short periods of ischaemia [28]. Apparently, 
other mechanisms may have contributed to the acti­
vation of K ATP channels as reviewed previously [15],
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including localized decreases of ATP-concentration 
in a submembranous compartment of the cell [29, 
30], endothelial release of a hyperpolarizing factor 
(endothelium derived hyperpolarising factor) [31], 
an increase in the intracellular concentration of ade-
consequences of cardiovascular KAT[, channel block­
ade by sulphonylurea during the treatm ent of
NIDD M .
In summary, our results show that blockade of vas­
cular K AT1, channels by therapeutic concentrations of
nosine-5'-diphosphate [32], an increase in interstitial glibenclamide induce a slight, but significant, reduc- 
concentrations of the ATP-degradation product ade- tion in the vasodilator response to ischaemia in hu­
mans. This observation may be of relevance in sul- 
phonylurea-treated diabetic patients who suffer 
from ischaemic incidents.
nosine [33], and alterations in concentrations of 
Mg2 + [34] or pH [35].
In contrast to short-term parameters, total flow 
debt repayment after arterial occlusion was not sig­
nificantly inhibited by glibenclamide (Table 2). In­
deed, several reports have suggested that only the in­
itial cellular potassium efflux after ischaemia is medi­
ated by activation of KATP channels [36, 37]. The de­
layed vasodilator response to ischaemia seems pre­
dominantly to be mediated by other mechanisms, in­
cluding the endothelial release of endothelium-de­
rived nitric oxide [38] and prostaglandins [39, 40]. 
This may explain why total flow debt repayment can 
be inhibited by iVG-monomethyl-L-arginine (a spe­
cific inhibitor of nitric oxide-synthase) [38] or by ibu- 
profen (a prostaglandin synthase inhibitor) [39], but 
not by the KATF channel blocker glibenclamide. Inter­
estingly, some animal studies have shown a significant 
reduction of total flow debt repayment by glibencla­
mide [1, 41], However, it has to be emphasized that 
these experiments were performed in the coronary 
circulation of animals, and with the use of high glib­
enclamide concentrations. Moreover, in such experi­
ments glibenclamide has been shown to reduce basal 
coronary blood flow [37, 42]. In contrast, our experi­
ments were performed in the human forearm vascu­
lar bed with relatively low glibenclamide concentra­
tions. Actually, the lower density of sulphonylurea re­
ceptors in the skeletal muscle vascular bed, as com­
pared with the coronary circulation or with other 
ischaemia-sensitive tissues, may explain the afore­
mentioned differences in results [43, 44]. This, in re­
turn, may argue for more severe effects of blockade 
of Katp channels in the heart than in the forearm.
The current human in vivo observations show that 
therapeutic glibenclamide concentrations affect the 
reactive hyperaemic response in the forearm vascular 
bed, suggesting a blockade of vascular K ATP channels. 
If this glibenclamide effect also holds for the myocar­
dial Katp channels, it may have important effects on 
the outcome of ischaemic events in diabetic patients 
on sulphonylurea therapy. Some epidemiological 
studies have shown evidence of a higher cardiovascu­
lar mortality or morbidity in diabetic patients on sul­
phonylurea therapy as compared with other therapies 
[45—47]. However, the methodological basis of those 
studies has been criticized, and other investigators 
were not able to reproduce the harmful effects of sul­
phonylurea derivatives [48-50]. It is obvious that clin­
ical trials with well-defined end points (infarct size, 
arrhythmias) are necessary to elucidate the clinical
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